Atyr Pharma Inc LIFE Stock Forecast
AI-powered price prediction and analysis for Atyr Pharma Inc · Alpha · vs marketSwitch to Total
See LIFE's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Atyr Pharma Inc
Atyr Pharma Inc (LIFE) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
- aTyr Pharma, Inc. (ATYR) Stock Analysis: Exploring a Potential 1,458% Upside in the Biotech Sector
- ATyr Pharma, Inc. Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In The Journal Of Biological Chemistry
- aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2019 Results - Earnings Call Transcript
- Sign up free to read all 12 articles →
Where LIFE sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| LIFE Atyr Pharma Inc | ▲ | $2.46B | – |
| AMGN Amgen Inc | ▼ | $234.65B | 27.0x |
| GILD Gilead Sciences, Inc. | ▲ | $190.38B | – |
| MRNA Moderna, Inc. | ▲ | $90.35B | – |
| ARGX Argenx Se | ▼ | $50.64B | 21.5x |
| RVMD Revolution Medicines, Inc. | ▲ | $41.48B | – |
| BIIB Biogen Inc. | ▼ | $34.16B | 25.0x |
| BNTX Biontech Se | ▲ | $22.42B | 2.3x |
| EXEL Exelixis, Inc. | ▶ | $15.11B | 17.6x |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.82B | 19.7x |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.26B | 26.9x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| IBRX Immunitybio, Inc. | ▲ | $10.50B | – |
| RGEN Repligen Corp | ▶ | $10.06B | 258.2x |
| PCVX Vaxcyte, Inc. | ▲ | $10.05B | – |
| QGEN Qiagen N.V. | ▶ | $9.88B | 32.3x |
| KRYS Krystal Biotech, Inc. | ▶ | $9.79B | 41.5x |
| TWST Twist Bioscience Corp | ▲ | $9.29B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.88B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B | – |
| IMVT Immunovant, Inc. | ▲ | $5.76B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.48B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.10B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.86B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.82B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.08B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.74B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.17B | – |
| DNLI Denali Therapeutics Inc. | ▼ | $2.86B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.44B | 94.6x |
| ADMA Adma Biologics, Inc. | ▼ | $2.40B | 17.3x |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.25B | – |
| NVAX Novavax Inc | ▲ | $2.08B | – |
| VCEL Vericel Corp | ▲ | $2.06B | 85.1x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B | – |
| ALVO Alvotech | ▲ | $1.90B | – |
| MESO Mesoblast Ltd | ▶ | $1.77B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.76B | – |
| IMCR Immunocore Holdings Plc | ▶ | $1.46B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.46B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▼ | $1.40B | – |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.22B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.14B | – |
| VOR Vor Biopharma Inc. | ▶ | $1.11B | – |
| REPL Replimune Group, Inc. | ▲ | $1.07B | – |
| JATT Zura Bio Ltd | ▶ | $994M | – |
| VALN Valneva Se | ▼ | $965M | – |
| IMTX Immatics N.V. | ▲ | $938M | – |
| MGTX Meiragtx Holdings Plc | ▶ | $904M | 12.2x |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $878M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $839M | – |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $798M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $776M | – |
| SANA Sana Biotechnology, Inc. | ▲ | $698M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $694M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $674M | – |
| AURA Aura Biosciences, Inc. | ▲ | $640M | – |
| SLDB Solid Biosciences Inc. | ▲ | $586M | – |
| PRME Prime Medicine, Inc. | ▲ | $568M | – |
| DBVT Dbv Technologies S.A. | ▶ | $525M | – |
FAQ
Is Atyr Pharma Inc a good stock to buy?
Our AI analyzes Atyr Pharma Inc daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Atyr Pharma Inc predictions?
For LIFE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 46.0%, measured on 122 forecast dates between 2026-01-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 11.0%, measured on 164 forecast dates between 2026-01-29 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Atyr Pharma Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Atyr Pharma Inc? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.